產(chǎn)品詳情
簡單介紹：
Anti-L3MBTL3抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-L3MBTL3抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-L3MBTL3
Cat. Number:
Anti-L3MBTL3抗體KL-12342R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Polycomb group (PcG) proteins are important for maintaining the transcriptionally repressed state of target genes and are thought to function via chromatin modification. PcG proteins assemble into multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cellAnti-L3MBTL3抗體 generations. PcG proteins are also required for normal maturation of myeloid progenitor cells. A putative PcG protein, L3MBTL3 (lethal(3)malignant brain tumor-like protein 3), also known as MBT-1 or KIAA1798, is a 780 amino acid protein containing three MBT repeats and one SAM (sterile alpha motif) domain. Localized to the nucleus, L3MBTL3 interacts with RING1B, another PcG protein that may be involved in the specification of anterior-posterior axis and cell proliferation in early development. L3MBTL3 exists as two isoforms produced by alternative splicing events.
Also known as:
Hl(3)mbt like protein; KIAA1798;Anti-L3MBTL3抗體 l(3)mbt like 3 (Drosophila); l(3)mbt like 3; L(3)mbt like 3 protein; Lethal(3)malignant brain tumor like 3 protein; MBT1; LMBL3_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated syntheticAnti-L3MBTL3抗體 peptide derived from human L3MBTL3.
●
Predicted Molecular Weight: 88kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-L3MBTL3抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
